

Keyword Index for Volume 104

- ¹H-MRS 1854
4T1 cell 128
- 5-aminolevulinic acid 798
5-fluorouracil 1067, 1459
5-FU 1691
- 8q24.3 376
- α -TEA 101
actin cytoskeleton 781
activated Kras 1038
activin 1303
acute lymphoblastic leukaemia 12, 746
acute myeloid leukaemia 1482
adenocarcinoma 700, 1296
adenoma–carcinoma sequence 1426
adhesion 345
adipose tissue 441
adjuvant chemotherapy 559
adjuvant treatment 899
adoptive transfer 948
adverse events 899
AGC diagnosis 353
age 564
aggressive fibromatosis 1452
Akt 101, 1755
AKT/PKB and S6K 1116
albumin 726
alcohol 537, 1487
ALKBH3 700
allele-specific expression 735
allelic imbalance 735
ambulatory care 1377
analgesics 532, 1704
anastrozole 1059
angiogenesis 83, 166, 635, 819, 1144, 1185, 1628, 1822, 1877
angiopoietin-2 51
anthracycline resistance 1071
anticancer agent 448, 635
anticancer immunotherapy 300
anticoagulation 413
antifolates 272
antimetabolites 272
anti-metastatic 635
anti-oestrogen therapy 1828
anxiety 255, 578
AP-1 1920
APC 1452
apoptosis 91, 235, 437, 781, 1151, 1278, 1459, 1594
apoptosis and multiple myeloma 957
ARHGEF16 324
ARMS 982
aromatase inhibitors 1059, 1558
array-CGH 361, 376
Asian population 871
ASPM 1602
- astrocytic tumours 968
astrocytoma 1747
attenuated total reflection Fourier-transform infrared spectroscopy 790
attitudes 1535
autoantibodies 1896
auxological 746
avoidable deaths 1836
AZD1152 769
- β -1 integrin 1587
 β -catenin 1452
Bag-1 1459
balancing baseline covariates 1711
basal 120
Bcl-2. 120
bevacizumab 413, 599, 1079, 1262, 1270
bim 281
biomarkers 719, 1144, 1262, 1313, 1325, 1602, 1755, 1896
bladder cancer 376, 808, 1135, 1869
BMP-7 714
body mass index 746, 871, 921, 1207
bone metastasis 505, 613
BRAF 392, 856
BRAF^{V600E} 392
brain 1877
brain metastasis 1816
brain tumour stem cell 448
BRCA1 316, 903, 1349, 1356, 1384
BRCA2 1356, 1384
breast cancer 6, 101, 128, 332, 338, 419, 524, 559, 564, 571, 578, 871, 899, 910, 1059, 1214, 1342, 1356, 1384, 1551, 1558, 1628, 1656, 1680, 1716, 1730, 1828
Breast Cancer Index 1762
breast cancer mortality 910
breast cancer stem cells 1564
breast conservation 1551
breast density 871
breast neoplasms 60, 520
breath 1649
BRG1 146
brick dust 1797
BRM 146
- CA125 863, 989
cachexia 441
CA-IX 353
cancer awareness 1836
cancer chemotherapy 448
cancer management 1246, 1535
cancer progression 841
cancer registry 564
cancer risk 1493
cancer stem cells 1410, 1730
- cancer-associated inflammation 1288
cancer-predisposing gene 735
capecitabine 43, 1067, 1071
capture-recapture 1227
carcinogenesis 208, 229
case–control studies 175, 188, 875, 910, 1207, 1482
caspase-8 281, 1278
castrate-resistant prostate cancer 613, 1920
cathepsin B 957
CD9 496
CD9P-1 496
CDK inhibitor 1862
CDX2-positive circulating tumour cells 1000
celecoxib 1822
cell cycle 235, 1523
cell line 968
cell migration 345
CellSearch system 1472
cell-to-cell interaction 505
central venous blood 1472
centrosome 1523
c-erb-b2 1739
cerebrovascular disease 899
cervical cancer 361, 685, 971
cervical cancer precursors 110
cervical cancer prevention 248
cervical intraepithelial neoplasia 685
cervix 353, 1500
cetuximab 427, 488, 1691, 1786
chemoradiotherapy 265, 361
chemoresistance 19, 707, 1730
chemoresistant breast cancer 1401
chemotherapy 407, 750, 856, 1670, 1810, 1840
Chernobyl nuclear accident 181
childhood 746
childhood cancer 214, 1227
childhood leukaemia 12, 1227
China 1511
Chinese 369
cholangiocarcinoma 24, 587, 1313
choline and phosphocholine release, MARCKS 673
chromosomal instability 1724
chronic disease 399
cilengitide 1691
CIP2A 1890
circulating endothelial progenitor cells 1144
circulating tumour cells 1178, 1472, 1913
cisplatin 265, 593, 1071, 1098, 1126, 1278, 1691
citation network analysis 1085
clear cell 1151
clinical trials 1529, 1535
cohort 419, 537, 1196, 1500, 1511
- colon cancer 33, 769, 882, 1178, 1202, 1426
colon polyp 882
colorectal cancer 6, 43, 60, 146, 188, 193, 369, 413, 480, 488, 856, 893, 934, 1000, 1007, 1013, 1020, 1079, 1085, 1262, 1270, 1288, 1434, 1619, 1697, 1770, 1779, 1786, 1791, 1906
colorectal cancer predisposition 735
colorectal cancer survival 763
colposcopy 255
combination chemotherapy 272
combinatorial therapy 399
co-morbidity 60
complete case analysis 693
compliance 1558
concordance 1020
contralateral breast cancer 1384
cost effectiveness 1377
coumarin 91
COX-2 763, 819
coxsackie adenovirus receptor 1426
C-reactive protein 51, 726
CRPC 605, 620
CTC 1913
CTL 300
cucurbitacin IIa 781
cutaneous melanoma 982
CXCL1 480
CXCL8 480
CXCL9 469
CXCR1 480
CXCR2 480
CXCR4 1805
cyclin D1 146
CYP2A6 1126
CYP450R 1098
cytokeratin 1434, 18 719
cytology 1325
cytotoxic CD8⁺ T cells 948
- dacarbazine 750, 1816
DCIS 120
DcR1 1313
DDS 593
delayed diagnosis 934, 1249, 1836
delayed-type hypersensitivity 433
deleted in oesophageal cancer 1 (DEC1) 841
deoxyribose 1185
depression 255
deprivation 1505, 1791
desmoid tumour 37
desmoid-type fibromatosis 37
dexmethasone 605, 620
diagnosis 110, 1325, 1418
diagnostic imaging 1482

- diagnostic marker 893
 dietary patterns 524, 1493
 diethylstilbestrol 605, 620
 differentiation therapy 229
 disseminated tumour cells 1434
 distant metastasis 1724
 distress 255, 419
 disulfiram 1564
 DNA damage 1869
 DNA methylation 1013, 1313
 DNA microarray 1027
 DNA repair 653, 1349
 DNA-PK 1724
 docetaxel 265, 613
 dormancy 1628
 doxorubicin 437, 559, 957
 DR5 281, 1278
 drug resistance 272
 DSC3 1013
 dynamic allocation 1711
 dysplasia 460
- early death 1544
 early diagnosis 1836
 early presentation 1836
 early-onset breast cancer 903
 early-stage breast cancer 1913
 education 520
EGFR 338, 488, 968, 989, 1135
EGFR family 1241
EGFR promoter methylation 1786
 elderly 1393
 EMT 989
 end of life 1704
 endocrine therapy 1393
 endometrial cancer 790, 921,
 1418, 1207, 1505, 1611, 1836
 endometrium 790
 endothelial monolayer
 breakdown 469
 enrichment 1913
 EpCAM 1434
 epidemiology 532, 763, 1202, 1493
 epidermal development 229
 epidermal growth factor
 receptor 1575
 epigenetic 1500
 epigenome 554
 epirubicin 613
 epithelial ovarian cancer 1602
 epithelial–mesenchymal
 transition 1160
 EPR effect 593
 Epstein-Barr virus 332
 ER 1393
 ERBB2 1135, 1739
 ErbB2/HER2 1716
 ERBB3 1135, 1241
 ERCC1 1126
 ERK 101
 Ewing tumour 948
 exemestane 1059
 exon array 971
 expression profiling 971
 extracapsular spread 850
- factor analysis 524
 factor VII 1401
- faecal occult blood testing 1779
 faeces 1770
 familial adenomatous
 polyposis 37
 febrile neutropenia 407
 ferrochelatae 798
 fever 1377
 FFPE 971
 FGFR1 75
 FGFR3 75
 fibreglass 1797
 figitumumab 68
 FIH-1 1151
 first generation immigrants
 1193
 FISH 1372
 FKBP5 19
 FLT3 ligand 719
 fluid 1487
 fluorescence 798
 fluorescence *in situ*
 hybridisation 850
 folate transporters 272
 FOLFOX-4 427
 fruit 6
 fuzetaxis 469
 FXR 1027
- G1/S checkpoint 1862
 gall bladder cancer 587
 GalNAc-T3 1882
 GalNAc-T6 1882
 gastric cancer 166, 714, 1126,
 1372, 1511, 1840
 gastrointestinal cancer 441
 gastrointestinal stromal tumour
 1686
 GC-MS 1649
 GDF15 1619
 gemcitabine 769, 1071
 gene expression profiling 545,
 1762
 genetic 369, 1049
 GLI1 1575
 glioblastoma 545, 968, 1365,
 1805, 1810
 glioma 193, 545, 653, 798
 glutathione 437
 GPRD 193
 growth factor 1641
 GTD 1665
 GUT-70 91
- haemorrhage 413
 hand pattern 175
 HCG 1665
 HDAC 1828
 HDAC inhibitors 957, 1828
 HE4 863, 1418
 head and neck cancer 830, 1641,
 1649, 1896
 head and neck squamous cell
 carcinoma 1319
 heat shock protein 643
 heat shock protein-70 1459
 hedgehog 1575
Helicobacter pylori 198, 1511
 heparan sulfate 635
- heparanase 635
 hepatectomy 1007
 hepatic metastasectomy 1085
 hepatitis B reactivation 559
 hepatocellular carcinoma 24, 1303
 HER2 332, 1372, 1739, 1920
HER2 amplification 1342
 HER2 positive 1675
 HER2/neu 1739
 herbal medicines 927
 herpesviruses 433
 heterogeneity 361, 1739
 H-HPV 353
 HIF-1 α 166, 1151
 HIF-2 α 1151
 Hippo 24
 histological type 198
 histology 714, 971, 1505
 histone deacetylase 756, 1828
 history of medicine 1085
 HLA-transgenic mouse 300
 Hodgkin and non-Hodgkin
 lymphoma 719
 Hoechst 33342 dye 1410
 hormone therapy 763
 HPV 830, 886, 915, 1334, 1896
 HPV prevalence, unvaccinated
 adolescents, Scotland 1221
 HPV test 248
 HPV16 E6 324
 Hsp90 91, 629
 human apurinic/aprimidinic
 endonuclease 1 (APE1) 653
 human immunodeficiency virus
 (HIV) 433
 HuR 819
 hyperglycaemia 345
 hyperinsulinemia 345
 hyperplasia 460
 hypertension 599
 hyperthyroidism 1665
 hypothyroidism 241
 hypoxia 166, 1319
- IBC 1575
IDH1 968
 IGF-1 68
 IGFBP-2 1587
 IGF-independent 1587
 IGF-IR 68
 IL-1 128
 imatinib 1686
 immunohistochemistry 110,
 1372, 1440, 1459, 1594
 immunophilins 19
 immunoRNase 1716
 immunosuppression 1334
 immunotherapy 948, 1106,
 1256, 1716
 incidence 178, 1505, 1791
 industry 208
 infants 532
 infection 407
 influenza 1670
 infrared spectroscopy 790
 inhibin 1303
 iNOS 83
 in-patients 1377
- insulin resistance 51
 integrin 33
 interleukin-2 1256
 interval cancer 571
 intrinsic subtypes 120
 invasion 155, 1038
 invasive phenotype 664
 iodine deficiency 181
 iodine radioisotopes 181
 ionising radiation 1049, 1482
 irradiation 1805
 irritable bowel syndrome 1202
 IRS-1 101
 Italy 433
- JAK2/STAT3 781
- Kaposi sarcoma 433
 KIF20A/RAB6KIFL/MKlp2 300
 kinase inhibitor 1116
 KRAS 856
 KRAS mutation 1020
- laser-capture microdissection 464
 late effects 746
 latent membrane protein 1 1160
 lead time bias 1680
 leptin 128
 letrozole 1059
 leukaemia 12, 532
 ligand-targeted photodynamic
 therapy 1401
 lipolysis 441
 liver cancer 24, 235
 liver fluke 1313
 liver function tests 726
 liver metastases 1020, 1079
 LLETZ 255
 low-dose chemotherapy 1822
 low-grade glioma 1747, 1854
 luminex 1896
 lung cancer 6, 208, 496, 700,
 1649, 1704
 LY6K 376
 lymph node 850
 lymph node metastasis 1027
- malignancy 1478
 mammalian reovirus 290
 mammography 871, 1214
 mammography screening 571
 management 37, 564, 1810
 mantle cell lymphoma 91
 MAP kinase pathway 1920
 MAPK pathway 1564
 MARIBS 578
 marital status 1249
 marker protein patterns 110
 mastectomy 1551
 meat 1196
 Mediterranean diet 1493
 MEK/ERK 982
 melanoma 155, 392, 643, 653, 750
 melanoma progression 982,
 1816
 meningioma 1049
 merkel cell carcinoma 178
 merkel cell polyomavirus 178

- mesothelioma 1325
meta-analysis 1196, 1440
metastasis 235, 629, 1007, 1038, 1160, 1270, 1877, 1882
metastatic breast cancer 1071, 1472, 1675
metastatic colorectal cancer 1848
metastatic renal cell carcinoma 1144
methotrexate 272
methylation 1500, 1770, 1906
MIC-1 1619
microarrays 545
microcephalin 1602
microRNA 235, 808, 1168
microsatellite instability 1906
migration 1270, 1575
mineral wool 1797
minimisation 1711
miR-584 308
miR-1 808
miR-133a 808
miR-148a 1770
miR-34b/c 1770
miRNA 830, 893
missing covariates 693
mitochondria 629
mitochondrial DNA 1319
mitomycin C 1098
mitosis 1523
molecular detection 1178
molecular targeted therapy 941
monoclonal antibody 1106
monoHER 437
mortality 60, 934
motility 308, 1038
mouse model 1452
MRI 578, 1116, 1854
mRNA 819
MRP2 expression 707
mTOR 101, 643, 741
MUC16 989
mucins 989
multidisciplinary clinic 1246
multidrug resistance protein 2 707
multimer technology 948
multiple imputation 693
multivariate analysis 790
mutations 1319
myeloma 281
- nasopharyngeal carcinoma 1160
natural killer cells 1106
NC-6004 593
NDPK 1628
neo-adjuvant chemotherapy 707
neovascular- and cancer cell-targeting photodynamic therapy 1401
neuregulin 1135
neuroendocrine tumour 1067
neutropaenia 1377
neutropenic sepsis 407
neutrophil/lymphocyte ratio 1288
NF- κ B 166, 1564
NICE guidance 1810
ninein-like protein 1523
- nitric oxide 83
Nlp 1523
nodal involvement 714
non-compliance 685
non-Hodgkin's lymphoma 1862
non-melanoma skin cancer 1334
non-small cell lung cancer 413, 1594, 1877
non-small cell lung tumour cells 1410
nonsmokers 208
normal tissue effects 1365
normalisation 1168
North East Netherlands 1193
NSAIDs 763
NSCLC 68, 316
nuclear factor- κ B 437
nuclear receptor 448
nuclear sites 12
nucleosomal DNA 719
nucleotides 1628
- obesity 51, 875
occupation 208
occupational dust exposure 1797
oesophageal cancer 265, 427
oesophageal cancer family history 841
oesophageal squamous cell carcinoma 707, 841
oestrogen 338
oestrogen receptor 1828
oligodendroglioma 1747
oncogene mutation 464
oncologists 1535
oncolysis 290
OPCML 1313
oral cavity 850
oral squamous cell carcinoma 460, 830
oropharyngeal cancer 886
osteoclastogenesis 505
osteopontin 1007
oval cells 24
ovarian ascites 1602
ovarian cancer 863, 989, 1196, 1241
oxaliplatin 43, 769
- p16^{INK4a} 1334
p53 91, 1013, 1278
paclitaxel 1564
pain 1704
palliative care 1704
pancreas 1296
pancreatic cancer 769, 1027, 1038, 1440, 1882
pancreatic cancer-gene expression in 514
panitumumab 1848
Pap-test 248
PARP 750
partner avoidance 1249
partner support 1249
pathologic complete response 1840
patient recruitment 1529
PD 0332991 1862
- PD173074 75
pemetrexed 1594
pepinogens 1511
peripheral blood lymphocytes 1724
peripheral venous blood 1472
persistence 1558
persistent infection 290
personalised screening 1656
personalised therapy 545
pharmacodynamic 756
pharmacoepidemiology 188, 1558
pharmacokinetic 756
phase I study 593, 756
phospholipase 338
phosphorylation 1755
photodynamic therapy 798, 1106
physical activity 882
physical contact 505
PI3K-Akt signalling pathway 146
PI3K-AKT-mTOR 392
PML-RAR α 554
poly(A) cDNA 514
polygenic risk 1656
polymer micelle 593
polymorphism 1126
population mixing 12
population-based screening programme 685
postoperative early relapse 1178
post-traumatic stress symptoms 419
prediction 1544
predictive factor 599
preoperative chemoradiotherapy 427
prescription 1704
prevalence 927
primary breast cancer 1393
primary head and neck cancer 1246
primary health care 934
primary systemic therapy 1730
progesterone receptor 921
prognosis 545, 707, 714, 921, 1013, 1168, 1288, 1296, 1418, 1440, 1641, 1680, 1724, 1747, 1762, 1882, 1890, 1913
prognostic factors 564
prognostic markers 856, 893, 1434, 1611, 1619
prolactin receptor 1641
proliferation 345, 1641
prospective studies 419, 524, 1196, 1487
prostate cancer 175, 505, 613, 629, 664, 875, 1656, 1920
prostate epithelial cell lines 673
prostate-specific antigen 613
protein kinase B 1755
protein kinase C, phospholipase D 673
PROX1 1747
proximal tumours 763
psychology 578
PTEN 146, 1587
PTSD 419
PU.1 (SPI1) 554
pulmonary metastasectomy 1085
- punch biopsies 255
purinergic receptors 1628
pyrosequencing 735
- quality of life 587, 1697
quality-adjusted survival 1848
quantitative PCR 1342, 1913
quantitative RT-PCR 514
- R132H 968
Rab proteins 33
Rab11-FIP 33
radiation 1214
radiation therapy 1365, 1840
radiography 1482
radiotherapy 1724, 1810
Raf 1920
Raf kinases 229
raltitrexed 1869
randomised clinical trial 1816
Ras pathway 229
RAS-RAF-MEK-ERK 392
Rassf polypeptides 24
reactive oxygen species 1564
real-time PCR 332, 1303, 1739
recruitment 1535
recurrence 1762
reduced toxicity 290
registration 1227
relative survival 564
renal cancer 741, 1151
renal cell carcinoma 241, 308, 399, 537, 643, 941, 1256, 1487, 1797
renal transplantation 1334
replication 369
replication inhibitor 1098
resistance 750, 1270
retinoblastoma-positive solid tumours 1862
Rho proteins and Cdc42 324
RhoA 781
risk 181, 1202
risk assessment 1762
Risk of Ovarian Malignancy Algorithm 863
ROCK-1 308
RT-PCR 514
RXR 554
- S-1 1126
safety 413, 1691
salt intake 198
SCCHN 1691
Scotland 60
screening 248, 910, 915, 1214, 1680, 1779
SDF-1 1805
second cancer 178
selection 361
selective serotonin reuptake inhibitors 188
self-sampling 915
senescence 700
sensitivity 1049
sensor 1649
sequential therapy 399
serum marker 1418

- SGK 1116
side population 1410
sigmal 290
signalling 664, 1628
single-cell PCR 464
single-nucleotide
 polymorphisms 893
siRNA 1027
skin 1459
SLE 1478
Smad3 33
small molecule inhibitors 653
smoking 198, 1500
Snail 1160
snoRNA 1168
social class 520
social support 1249
socioeconomic circumstance 1791
soft tissue sarcoma 437, 1544
sorafenib 941, 1256
SOX2 1410
squamous cell carcinoma 850,
 1106
squamous cell carcinoma of the
 head and neck (HNSCC) 138
squamous cervical cancer 110
stomach cancer 1193
stomach neoplasms 198
subcellular localisation 841
sunitinib 241, 741, 1686
sunitinib malate 399
sunlight 214
surgery 1393, 1810, 1840
survival 60, 726, 1246, 1680,
 1747, 1890
survivin 781, 941
survivorship 927
systematic review 1196
systemic lupus 1478
TACE 138
TAGLN2 808
tamoxifen 899, 1558
targeted therapy 399, 464, 1256,
 1686
taxanes 316
temozolomide 1816, 1854
temsirolimus 643
testosterone 1452
tetraspanin 496
tetraspanin 8 155
tetraspanin CD151 1611
TFII-I 1349
TGFBR1 735
Thiothymidine 1869
thymidine kinase 332
thymidine phosphorylase 1185
thymidine phosphorylase
 inhibitor 1185
thymidylate synthase 1594
thyroid atrophy 241
thyroid neoplasms 181
TIMP3 138
Tip-1 324
tissue factor 1401
tissue micro-arrays 693
TKI-258 75
toll-like receptor 2 460
tongue cancer 1890
toxicity 756, 1365
TRAIL 281, 1278
TRAMP 629
transcription factor 1410
transendothelial migration 469
transplantation 433
Trastuzumab 1675, 1716
treatment decision making 1551
treatment sequencing 605, 620
treatment variation 1551
tricyclic antidepressants 188,
 193
triple negative 120
TSP1 316
tumour angiogenesis 51
tumour endothelial cells 819
tumour growth 166, 496
tumour markers 1342, 1755
tumour morphology 903
tumour neovasculation 1106
tumour regrowth 1805
tumour response 1854
tumour site 198
tumour suppressor pathway 24
tumour thickness 982
tumour vaccine 643
tumour-associated antigen
 300
tumourigenesis 1523
twin study 520
TXR1 316
type 1 1505
type 2 1505
type II 1611
tyrosine kinase inhibitor 75,
 1144, 1686
UICC stage II/III 1178
urothelial carcinoma 75
UVA 1869
uveal melanoma 1098
vaccine 1670
vascular 1877
vasculogenesis 1805
vatalanib 1686
vegetables 6
VEGF 128, 741, 1262, 1270
VEGF-A 819
VEGFR2 128
vesicle trafficking 33
vimentin 1296
vinorelbine 1071
vitamin D 214
volatile biomarker 1649
V-raf murine sarcoma
 viral oncogene homologue
 B1 464
waist-to-hip ratio 1207
waiting lists 934
Warburg effect 345
weight 746
Wnt 1906
xenograft 941
XIAP 1575
XRCC1 1356
zinc- α 2-glycoprotein 441